Dataset from Multicenter Extension Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
收藏NIAID Data Ecosystem2026-05-02 收录
数据链接：
官方服务：
资源简介：
Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
应用场景：
创建时间：
2024-11-26
相关数据集
Dataset from A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis
The primary purpose for this study is to help answer the following research questions - The safety of ixekizumab (LY2439821) and any side effects that might be associated with it. - Whether ixek
NIAID Data Ecosystem30
Supplemental material for JAAD publication titled: Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study
Supplemental material for JAAD publication titled: "A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe p
Mendeley Data10
Supplemental material for JAAD publication titled: Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study
Supplemental material for JAAD publication titled: "Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a P
Mendeley Data2020-11-12 更新10
Dataset from A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiv
NIAID Data Ecosystem20
Supplementary Materials for: Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2 trial
This dataset contains supplementary materials for the following publication: Novel TYK2 inhibitor D-2570 in moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase 2
NIAID Data Ecosystem10
